Comparison of Serratus Posterior Superior Intercostal Plane Block and Deep Serratus Anterior Plane Block After Video-Assisted Thoracoscopic Surgery

NCT07553195 | Not Yet Recruiting

• 1 other identifier: SPSIP-Deep SAP-VATS
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective interventional study aims to evaluate and compare the analgesic efficacy of the Serratus Posterior Superior Intercostal Plane (SPSIP) and Deep Serratus Anterior Plane Block in patients undergoing Video-Assisted Thoracoscopic Surgery. The primary outcome is Visual Analog Scale (VAS) during the first 24 hours after surgery. Secondary outcomes include total opioid consumption, requirement for rescue analgesia, block performance time, block-related and systemic side effects (hematoma, pneumothorax, local anesthetic toxicity, vascular puncture, infection), Patient satisfaction assessed using a Likert scale, Quality of recovery assessed using the QoR-15 questionnaire.

Conditions

Postoperative Pain; Video Assisted Thoracic Surgery (VATS); Serratus Posterior Superior Intercostal Plane Block; Deep Serratus Anterior Plane Block

Keywords

spsıp; vats; sap; Serratus posterior superior intercostal block; deep serratus anterior plane block

Outcome Measures

Primary Outcomes (1)

• Postoperative pain intensity assessed using the Visual Analog Scale (VAS)

  Postoperative pain intensity (VAS score) Postoperative pain will be assessed using the visual analog scale (VAS), ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst imaginable pain. Higher scores represent greater pain intensity. Measurements will be recorded at predefined time points within the first 24 hours after surgery.

  0, 1, 4, 8, 12, and 24 hours after surgery

Secondary Outcomes (8)

• Total opioid consumption via patient-controlled analgesia (PCA)

  Within the first 24 hours postoperatively

• Requirement for rescue analgesia

  Within the first 24 hours postoperatively

• Block performance time

  During the block procedure (intraoperative period)

• Block-related and systemic side effects

  Within the first 24 hours postoperatively

• Patient and Surgeon satisfaction assessed using a Likert scale

  At 24 hours postoperatively

Study Arms (2)

Serratus Posterior Superior Intercostal Plane Block

ACTIVE COMPARATOR

Procedure: Serratus Posterior Superior Intercostal Plane (SPSIP) block

Deep Serratus Anterior Plane Block

ACTIVE COMPARATOR

Procedure: Deep Serratus Anterior Plane Block (Deep SAP)

Interventions

Serratus Posterior Superior Intercostal Plane (SPSIP) block PROCEDURE

Patients in this group will receive an ultrasound-guided Serratus Posterior Superior Intercostal Plane (SPSIP) block with 30 mL of 0.25% bupivacaine hydrochloride injected into the fascial plane between the serratus posterior superior muscle and the third rib, 30 minutes before surgery.

Serratus Posterior Superior Intercostal Plane Block

Deep Serratus Anterior Plane Block (Deep SAP) PROCEDURE

Patients in this group will receive an ultrasound-guided Deep Serratus Anterior Plane Block (Deep SAP) with 30 mL of 0.25% bupivacaine hydrochloride injected into the fascial plane between the serratus anterior muscle and the external intercostal muscles at the level of the 5th rib in the mid-axillary line.

Deep Serratus Anterior Plane Block

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients aged 18-65 years
• ASA physical status I-III
• Scheduled for elective video-assisted thoracoscopic surgery
• Body mass index (BMI) between 18 and 35 kg/m²
• Ability to understand and use the patient-controlled analgesia (PCA) device
• Ability to provide written informed consent

You may not qualify if:

• Refusal to participate
• Allergy to local anesthetics
• Infection at the injection site
• Coagulopathy or ongoing anticoagulant therapy
• Chronic opioid use or opioid dependence
• Severe hepatic or renal insufficiency
• Pregnancy or breastfeeding
• Cognitive impairment or inability to communicate pain scores
• Body mass index (BMI) \<18 or \>35 kg/m²

Sponsors & Collaborators

• Antalya City Hospital: lead

Study Sites (1)

Antalya City Hospital

Antalya, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Pain, Postoperative; Lymphoproliferative Disorders

Interventions

Dental Occlusion

Condition Hierarchy (Ancestors)

Postoperative Complications; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Pain; Neurologic Manifestations; Signs and Symptoms; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Dentistry; Dental Physiological Phenomena; Digestive System and Oral Physiological Phenomena

Central Study Contacts

MUSTAFA KILIN, SPECİALİST İN ANESTHESİA

CONTACT

+905464569218; mustafa.kilin90@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Consultant Anesthesiologist

Study Record Dates

• First Submitted: April 13, 2026
• First Posted: April 27, 2026
• Study Start (Estimated): November 30, 2026
• Primary Completion (Estimated): December 30, 2027
• Study Completion (Estimated): April 30, 2028
• Last Updated: May 5, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)